Skip to main content
SpringerLink
Log in

Hepatoma derived growth factor (HDGF) dynamics in ovarian cancer cells

  • Published:
Apoptosis Aims and scope Submit manuscript

Abstract

As a leading cause of cancer death among women, identification of pathophysiologically-relevant biomarkers for ovarian cancer is important. The heparin binding, hepatoma-derived growth factor (HDGF) is overexpressed in ovarian cancer cell lines and may have prognostic value, but the mechanism by which this predominantly nuclear protein is secreted or functions is unknown. In this study, we focused on the circumstances under which HDGF is released by cells and the functional relevance of extracellular HDGF in the context of ovarian cancer. Immunofluorescence imaging showed nuclear localization of HDGF in ovarian cells, but unlike what is reported for other cell types, HDGF was minimally secreted into the media. However, HDGF was passively released by necrotic and late apoptotic cells. Extracellular HDGF was functionally relevant as it stimulated phosphorylation of ERK 1/2 and P38 in both non-cancer and ovarian cancer cells, and enhanced cellular migration. Overall, our study uncovers a novel function of HDGF as a messenger of cellular condition (alarmin) which in-turn modulates cellular function-aspects that could be used as a biomarker for ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Nakamura H, Kambe H, Egawa T, Kimura Y, Ito H, Hayashi E, Yamamoto H, Sato J, Kishimoto S (1989) Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta 183(3):273–284. doi:10.1016/0009-8981(89)90361-6

    Article  CAS  PubMed  Google Scholar 

  2. Nakamura H, Izumoto Y, Kambe H, Kuroda T, Mori T, Kawamura K, Yamamoto H, Kishimoto T (1994) Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem 269(40):25143–25149

    CAS  PubMed  Google Scholar 

  3. Abouzied MM, Baader SL, Dietz F, Kappler J, Gieselmann V, Franken S (2004) Expression patterns and different subcellular localization of the growth factors HDGF (hepatoma-derived growth factor) and HRP-3 (HDGF-related protein-3) suggest functions in addition to their mitogenic activity. Biochem J 378(Pt 1):169–176. doi:10.1042/bj20030916

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Lepourcelet M, Tou L, Cai L, Sawada J-i, Lazar AJF, Glickman JN, Williamson JA, Everett AD, Redston M, Fox EA, Nakatani Y, Shivdasani RA (2005) Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF). Development 132(2):415–427. doi:10.1242/dev.01579

    Article  CAS  PubMed  Google Scholar 

  5. Enomoto H, Nakamura H, Liu W, Nishiguchi S (2015) Hepatoma-derived growth factor: its possible involvement in the progression of hepatocellular carcinoma. Int J Mol Sci 16(6):14086–14097. doi:10.3390/ijms160614086

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Liao F, Dong W, Fan L (2010) Apoptosis of human colorectal carcinoma cells is induced by blocking hepatoma-derived growth factor. Med Oncol 27(4):1219–1226. doi:10.1007/s12032-009-9362-1

    Article  CAS  PubMed  Google Scholar 

  7. Ren H, Chu Z, Mao L (2009) Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther 8(5):1106–1112. doi:10.1158/1535-7163.mct-08-0779

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Lin Y-W, Li C-F, Chen H-Y, Yen C-Y, Lin L-C, Huang C-C, Huang H-Y, Wu P-C, Chen C-H, Chen S-C, Tai M-H (2012) The expression and prognostic significance of hepatoma-derived growth factor in oral cancer. Oral Oncol 48(7):629–635. doi:10.1016/j.oraloncology.2012.01.014

    Article  CAS  PubMed  Google Scholar 

  9. Li M, Shen J, Wu X, Zhang B, Zhang R, Weng H, Ding Q, Tan Z, Gao G, Mu J, Yang J, Shu Y, Bao R, Ding Q, Wu W, Cao Y, Liu Y (2013) Downregulated expression of hepatoma-derived growth factor (HDGF) reduces gallbladder cancer cell proliferation and invasion. Med Oncol 30(2):1–8. doi:10.1007/s12032-013-0587-7

    Google Scholar 

  10. Yamamoto S, Tomita Y, Hoshida Y, Morii E, Yasuda T, Doki Y, Aozasa K, Uyama H, Nakamura H, Onden M (2007) Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol 14(7):2141–2149. doi:10.1245/s10434-007-9369-9

    Article  PubMed  Google Scholar 

  11. Chang K-C, Tai M-H, Lin J-W, Wang C-C, Huang C-C, Hung C-H, Chen C-H, Lu S-N, Lee C-M, Changchien C-S, Hu T-H (2007) Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. Int J Cancer 121(5):1059–1065. doi:10.1002/ijc.22803

    Article  CAS  PubMed  Google Scholar 

  12. Yamamoto S, Tomita Y, Hoshida Y, Takiguchi S, Fujiwara Y, Yasuda T, Doki Y, Yoshida K, Aozasa K, Nakamura H, Monden M (2006) Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res 12(1):117–122. doi:10.1158/1078-0432.ccr-05-1347

    Article  CAS  PubMed  Google Scholar 

  13. Yoshida K, Tomita Y, Okuda Y, Yamamoto S, Enomoto H, Uyama H, Ito H, Hoshida Y, Aozasa K, Nagano H, Sakon M, Kawase I, Monden M, Nakamura H (2006) Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol 13(2):159–167. doi:10.1245/aso.2006.11.035

    Article  PubMed  Google Scholar 

  14. Ren H, Tang X, Lee JJ, Feng L, Everett AD, Hong WK, Khuri FR, Mao L (2004) Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non–small-cell lung cancer. J Clin Oncol 22(16):3230–3237. doi:10.1200/jco.2004.02.080

    Article  CAS  PubMed  Google Scholar 

  15. Zhao J, Yu H, Lin L, Tu J, Cai L, Chen Y, Zhong F, Lin C, He F, Yang P (2011) Interactome study suggests multiple cellular functions of hepatoma-derived growth factor (HDGF). J Proteom 75(2):588–602. doi:10.1016/j.jprot.2011.08.021

    Article  CAS  Google Scholar 

  16. Abouzied MM, El-tahir HM, Prenner L, Häberlein H, Gieselmann V, Franken S (2005) Hepatoma-derived growth factor: significance of amino acid residues 81–100 in cell surface interaction and proliferative activity. J Biol Chem 280(12):10945–10954. doi:10.1074/jbc.M414652200

    Article  CAS  PubMed  Google Scholar 

  17. Thirant C, Galan-Moya E-M, Dubois LG, Pinte S, Chafey P, Broussard C, Varlet P, Devaux B, Soncin F, Gavard J, Junier M-P, Chneiweiss H (2012) Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor. Stem Cells 30(5):845–853. doi:10.1002/stem.1062

    Article  CAS  PubMed  Google Scholar 

  18. Zhou Z, Yamamoto Y, Sugai F, Yoshida K, Kishima Y, Sumi H, Nakamura H, Sakoda S (2004) Hepatoma-derived growth factor is a neurotrophic factor harbored in the nucleus. J Biol Chem 279(26):27320–27326. doi:10.1074/jbc.M308650200

    Article  CAS  PubMed  Google Scholar 

  19. Arvizo RR, Giri K, Moyano D, Miranda OR, Madden B, McCormick DJ, Bhattacharya R, Rotello VM, Kocher J-P, Mukherjee P (2012) Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS ONE 7(3):e33650. doi:10.1371/journal.pone.0033650

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30. doi:10.3322/caac.21166

    Article  PubMed  Google Scholar 

  21. Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418(6894):191–195

    Article  CAS  PubMed  Google Scholar 

  22. Pallier C, Scaffidi P, Chopineau-Proust S, Agresti A, Nordmann P, Bianchi ME, Marechal V (2003) Association of chromatin proteins high mobility group box (HMGB) 1 and HMGB2 with mitotic chromosomes. Mol Biol Cell 14(8):3414–3426. doi:10.1091/mbc.E02-09-0581

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Petersen TN, Brunak S, von Heijne G, Nielsen H (2011) SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat Meth 8 (10):785–786. http://www.nature.com/nmeth/journal/v8/n10/abs/nmeth.1701.html#supplementary-information

  24. Bendtsen JD, Jensen LJ, Blom N, von Heijne G, Brunak S (2004) Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng Des Sel 17(4):349–356. doi:10.1093/protein/gzh037

    Article  CAS  PubMed  Google Scholar 

  25. Chen S-C, Hu T-H, Huang C-C, Kung M-L, Chu T-H, Yi L-N, Huang S-T, Chan H-H, Chuang J-H, Liu L-F, Wu H-C, Wu D-C, Chang M-C, Tai M-H (2015) Hepatoma-derived growth factor/nucleolin axis as a novel oncogenic pathway in liver carcinogenesis. Oncotarget. 6:16253

    Article  PubMed Central  PubMed  Google Scholar 

  26. Cayrol C, Girard J-P (2014) IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol 31:31–37. doi:10.1016/j.coi.2014.09.004

    Article  CAS  PubMed  Google Scholar 

  27. Harris HE, Raucci A (2006) Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep 7(8):774–778. doi:10.1038/sj.embor.7400759

    PubMed Central  CAS  PubMed  Google Scholar 

  28. Everett AD, Narron JV, Stoops T, Nakamura H, Tucker A (2004) Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol 286(6):L1194–L1201

    Article  CAS  PubMed  Google Scholar 

  29. Ooi BNS, Mukhopadhyay A, Masilamani J, Do DV, Lim CP, Cao XM, Lim IJ, Mao L, Ren HN, Nakamura H, Phan TT (2010) Hepatoma-derived growth factor and its role in keloid pathogenesis. J Cell Mol Med 14(6a):1328–1337. doi:10.1111/j.1582-4934.2009.00779.x

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Wang C-H, Davamani F, Sue S-C, Lee S-C, P-L Wu, Tang F-M, Shih C, Huang T-H, Wu W-G (2011) Cell surface heparan sulfates mediate internalization of the PWWP/HATH domain of HDGF via macropinocytosis to fine-tune cell signalling processes involved in fibroblast cell migration. Biochem J 433(1):127–138

    Article  CAS  PubMed  Google Scholar 

  31. Mao J, Xu Z, Fang Y, Wang H, Xu J, Ye J, Zheng S, Zhu Y (2008) Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci 99(11):2120–2127. doi:10.1111/j.1349-7006.2008.00928.x

    Article  CAS  PubMed  Google Scholar 

  32. Narron JV, Stoops TD, Barringhaus K, Matsumura M, Everett AD (2006) Hepatoma-derived growth factor is expressed after vascular injury in the rat and stimulates smooth muscle cell migration. Pediatr Res 59(6):778–783

    Article  CAS  PubMed  Google Scholar 

  33. Ke Y, Zhao W, Xiong J, Cao R (2013) Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells. FEBS Lett 587(18):3153–3157. doi:10.1016/j.febslet.2013.08.010

    Article  CAS  PubMed  Google Scholar 

  34. Guo H, Li W, Zheng T, Liu Z (2014) miR-195 Targets HDGF to inhibit proliferation and invasion of NSCLC cells. Tumor Biol 35(9):8861–8866. doi:10.1007/s13277-014-2153-0

    Article  CAS  Google Scholar 

  35. Kung M-L, Tsai H-E, Hu T-H, Kuo H-M, Liu L-F, Chen S-C, Lin P-R, Ma Y-L, Wang EM, Liu G-S, Liu J-K, Tai M-H (2012) Hepatoma-derived growth factor stimulates podosome rosettes formation in NIH/3T3 cells through the activation of phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun 425(2):169–176. doi:10.1016/j.bbrc.2012.07.060

    Article  CAS  PubMed  Google Scholar 

  36. Zhang J, Ren H, Yuan P, Lang W, Zhang L, Mao L (2006) Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res 66(1):18–23. doi:10.1158/0008-5472.can-04-3905

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Supported by the Department of Anesthesiology, Mayo Clinic and CA136494 (PM).

Author information

Authors and Affiliations

  1. Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA

    Karuna Giri

  2. Department of Anesthesiology, Mayo Clinic, 4-184 W Jos SMH, 200 1st St SW, Rochester, MN, 55905, USA

    Christina M. Pabelick & Y. S. Prakash

  3. Department of Physiology and Biomedical Engineering, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA

    Christina M. Pabelick & Y. S. Prakash

  4. Department of Pathology, University of Oklahoma Health Sciences Center, 1100 N Lindsay Ave, Oklahoma City, OK, 73104, USA

    Priyabrata Mukherjee

Authors
  1. Karuna Giri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christina M. Pabelick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Priyabrata Mukherjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. S. Prakash
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y. S. Prakash.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giri, K., Pabelick, C.M., Mukherjee, P. et al. Hepatoma derived growth factor (HDGF) dynamics in ovarian cancer cells. Apoptosis 21, 329–339 (2016). https://doi.org/10.1007/s10495-015-1200-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10495-015-1200-7

Keywords

Search

Navigation